Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Rivaroxaban

The articles shown below are all about the Rivaroxaban, through these related articles, you can get relevant information, notes in use, or latest trends about the Rivaroxaban. We hope these news will give you the help you need. And if these Rivaroxaban articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 24 2025

    2025-02-24

    This week, there are 12 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - VIFOR PHARMA INC's VELTASSA, containing active ingredient PATIROMER SORBITEX CALCIUM - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 17 2025

    2025-02-17

    This week, there are 7 drugs in the patent and exclusivity list. They are: - DURYSTA by AbbVie Inc, containing active ingredient Bimatoprost - IXEMPRA KIT by R-Pharm US LLC, containing active ingredient Ixabepilone - XIFAXAN by Salix Pharmaceuticals Inc, containing active ingredient Rifaximin - DIFFERIN by Galderma Laboratories LP, containing active ingredient Adapalene - NEXLIZET by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid; Ezetimibe ​- NEXLETOL by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid - XARELTO by Janssen Pharmaceuticals Inc, containing active ingredient Rivaroxaban Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 11 2024

    2024-11-11

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - KYOWA KIRIN INC's NOURIANZ, containing active ingredient ISTRADEFYLLINE - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - VANDA PHARMACEUTICALS INC's PONVORY, containing active ingredient PONESIMOD - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - BIOMARIN PHARMACEUTICAL INC's KUVAN, containing active ingredient SAPROPTERIN DIHYDROCHLORIDE - PROVENSIS LTD's VARITHENA, containing active ingredient POLIDOCANOL - BEIGENE USA INC's BRUKINSA, containing active ingredient ZANUBRUTINIB - SHIONOGI INC's FETROJA, containing active ingredient CEFIDEROCOL SULFATE TOSYLATE Read More